Needham Reiterates Buy on Cogent Biosciences, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Cogent Biosciences (NASDAQ:COGT) and maintained a price target of $22.
September 05, 2023 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Cogent Biosciences and maintained a price target of $22.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $22 price target indicates a positive outlook for Cogent Biosciences. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100